Familial Mediterranean Fever (FMF) is the most common monogenic auto-inflammatory disease [1]. Patients display attacks associating recurrent fever, arthritis, serositis and skin manifestations [1]. The discovery of the MEFV gene associated with the disease was made in the 1990s, and the diagnostic criteria are well established [2]. As a result, FMF has been widely studied and its treatment is well codified. The first-line treatment is colchicine [3]. Intolerance or resistance to colchicine is observed in 5 to 10% of cases [4], and effective alternative treatments have been developed, especially biotherapies targeting IL-1 (anakinra, canakinumab) [5].
